Amplyx Pharmaceuticals, a San Diego-based company developing antifungal agents for the treatment of life-threatening fungal infections, has appointed Michael Hodges as chief medical officer, Karen Shaw as vice president of biology, and Elizabeth Gordon as vice president of regulatory affairs. The firm recently raised an USD8.7 million investment from 3×5 Partners, increasing its series B financing to USD49.2 million.
“We have recruited a high-powered team with deep experience in anti-infectives to help advance the development of APX001,” noted Mike Grey, president and CEO of Amplyx.
Most recently Hodges was chief medical officer and head of drug development for Santaris Pharma A/S, that was acquired by Hoffmann-La Roche AG. He also held senior positions at Altair Therapeutics, Kemia and Pfizer Global Research and Development.
Shaw joined Amplyx from Hearts Consulting Group, where she provided consulting services to companies developing antibacterial and antifungal drugs. Prior to that, she served as senior vice president of biology at Trius Therapeutics, an antibiotic developer that was acquired by Cubist Pharmaceuticals.
Prior to joining Amplyx, Gordon served as vice president of regulatory affairs at Shire Pharmaceuticals and held the same position at Lumena Pharmaceuticals prior to its acquisition by Shire. CEO Grey also came from Lumena.
APX001 is a novel small molecule with a unique mechanism of action. In preclinical studies, the compound showed broad spectrum activity against infections caused by common species of Candida and Aspergillus, as well as high potency against rare molds.